PMID- 33579850
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 80
IP  - 2
DP  - 2021
TI  - Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in 
      Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective 
      Cohort Study.
PG  - 673-681
LID - 10.3233/JAD-201381 [doi]
AB  - BACKGROUND: Vascular factors and mitochondria dysfunction contribute to the 
      pathogenesis of Alzheimer's disease (AD). DL-3-n-butylphthalide (NBP) has an 
      effect in protecting mitochondria and improving microcirculation. OBJECTIVE: The 
      aim was to investigate the effect of donepezil combined NBP therapy in patients 
      with mild-moderate AD. METHODS: It was a prospective cohort study. 92 
      mild-moderate AD patients were classified into the donepezil alone group (n = 43) 
      or the donepezil combined NBP group (n = 49) for 48 weeks. All patients were 
      evaluated with Alzheimer's Disease Assessment Scale-Cognitive subscale 
      (ADAS-cog), Clinician's Interview-Based Impression of Change plus caregiver input 
      (CIBIC-plus), Alzheimer's Disease Cooperative Study-Activities of Daily Living 
      (ADCS-ADL), and Neuropsychiatric Inventory (NPI) every 12 weeks. All patients 
      were monitored for adverse events (AEs). The efficacy was analyzed using 
      multivariate logistic regression analysis. RESULTS: The multivariate logistic 
      regression analysis showed that the changes of ADAS-cog score (OR = 2.778, 95% 
      CI: [1.087, 7. 100], p = 0.033) and ADCS-ADL score (OR = 2.733, 95% CI: [1.002, 
      7.459], p = 0.049) had significant difference between donepezil alone group and 
      donepezil combined NBP group, while the changes of NPI (OR = 1.145, 95% CI: 
      [0.463, 2.829], p = 0.769), MMSE (OR = 1.563, 95% CI: [0.615, 3.971], p = 0.348) 
      and CIBIC-plus (OR = 2.593, 95% CI: [0.696, 9.685], p = 0.156) had no significant 
      difference. The occurrence of AEs was similar in the two groups. CONCLUSION: Over 
      the 48-week treatment period, donepezil combined NBP group had slower cognitive 
      decline and better activities of daily living in patients with mild to moderate 
      AD. These indicated that the multi-target therapeutic effect of NBP may be a new 
      choice for AD treatment.
FAU - Wang, Jin
AU  - Wang J
AD  - Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Guo, Xiaojuan
AU  - Guo X
AD  - Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Lu, Wenhui
AU  - Lu W
AD  - Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Liu, Jie
AU  - Liu J
AD  - Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Department of Neurology, Shaanxi Provincial People's Hospital, Xi'an, China.
FAU - Quan, Qingyun
AU  - Quan Q
AD  - Department of Gerontology, Shaanxi Provincial Corps Hospital, Chinese People's 
      Armed Police Forces, Xi'an, China.
FAU - Su, Hang
AU  - Su H
AD  - Department of Neurology, XiDian Group Hospital, Xi'an, China.
FAU - Ma, Li
AU  - Ma L
AD  - Department of Gerontology, The Ninth Hospital of Xi'an, Xi'an, China.
FAU - Gao, Fan
AU  - Gao F
AD  - Clinical Research Central, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Qu, Qiumin
AU  - Qu Q
AD  - Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Benzofurans)
RN  - 0 (Neuroprotective Agents)
RN  - 822Q956KGM (3-n-butylphthalide)
RN  - 8SSC91326P (Donepezil)
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*prevention & control/psychology
MH  - Benzofurans/adverse effects/*therapeutic use
MH  - Cognitive Dysfunction/*prevention & control/psychology
MH  - Cohort Studies
MH  - Donepezil/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuroprotective Agents/adverse effects/*therapeutic use
MH  - Neuropsychological Tests
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - DL-3-n-butylphthalide
OT  - clinical trial
OT  - drug treatment
OT  - prospective cohort study
EDAT- 2021/02/14 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/02/13 05:40
PHST- 2021/02/14 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2021/02/13 05:40 [entrez]
AID - JAD201381 [pii]
AID - 10.3233/JAD-201381 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2021;80(2):673-681. doi: 10.3233/JAD-201381.